Epithelial membrane antigen (EMA) or MUC1 expression in monocytes and monoblasts

Leong Chooi Fun, Osman Raudhawati, Soon Keng Cheong, Kulaveerasingam Sivagengei, Noor Hamidah Hussin

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Aims: Epithelial membrane antigen (EMA) or MUC1 belongs to a heterogeneous group of heavily glycosylated proteins and is expressed in most normal and epithelial neoplastic cells. EMA is also expressed in plasma cells, anaplastic large cell lymphoma (Ki-1 antigen), malignant histiocytosis and erythroleukaemia. In 1996, Cheong et al. (Hematology 1996; 1: 223) demonstrated the positive expression of EMA in monoblasts. Since there were very few useful markers for differentiating subtypes of acute myeloid leukaemia with a monocytic component from the those without, a study was conducted to evaluate the prevalence of EMA expression and its relationship with known markers for monocytic-macrophage lineage (CD11c, CD14 and intracellular CD68) in monocytes and monoblasts. Methods: EMA detection was performed by flow cytometry in monocytes and monoblasts. EMA expression was compared with other known markers of monocytic-macrophage lineage (CD11c, CD14 and intracellular CD68). Samples of purified monocytes were obtained from 20 healthy volunteers. Twenty-two cases of monocytic AML (M4 and M5) were studied and controls were selected from 20 cases of acute lymphoblastic leukaemia (ALL) and 18 cases of non-monocytic AML (MO, M1, M2, M3, and M7). Results: EMA was shown to be expressed strongly on the surface of all purified monocytes. EMA expression was observed on blast cells in 18/22 (81.8%) cases of AML M4 and M5, but not in that of non-monocytic AML or ALL. In this study EMA monoclonal antibody has demonstrated a strong association (P < 0.001) with all the other known markers of monocytic-macrophage lineage in acute leukaemia subtypes. EMA had also shown 100% specificity and 81.8% sensitivity in the diagnosis of AML M4 and M5. Conclusions: The monoclonal antibody EMA (clone E29) is a useful marker in the classification of acute myeloid leukaemia and can be used as a supplementary analysis for the diagnosis of acute leukemia with monocytic involvement.

Original languageEnglish
Pages (from-to)422-427
Number of pages6
JournalPathology
Volume35
Issue number5
DOIs
Publication statusPublished - Oct 2003

Fingerprint

Monocyte-Macrophage Precursor Cells
Mucin-1
Monocytes
Macrophages
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
CD30 Antigens
Monoclonal Antibodies
Histiocytic Sarcoma
Leukemia, Monocytic, Acute
Anaplastic Large-Cell Lymphoma
Leukemia, Erythroblastic, Acute
Hematology
Plasma Cells

Keywords

  • Acute myeloid leukaemia
  • Acute myeloid leukemia
  • EMA
  • Monoblasts
  • Monocytes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Epithelial membrane antigen (EMA) or MUC1 expression in monocytes and monoblasts. / Chooi Fun, Leong; Raudhawati, Osman; Cheong, Soon Keng; Sivagengei, Kulaveerasingam; Hussin, Noor Hamidah.

In: Pathology, Vol. 35, No. 5, 10.2003, p. 422-427.

Research output: Contribution to journalArticle

Chooi Fun, L, Raudhawati, O, Cheong, SK, Sivagengei, K & Hussin, NH 2003, 'Epithelial membrane antigen (EMA) or MUC1 expression in monocytes and monoblasts', Pathology, vol. 35, no. 5, pp. 422-427. https://doi.org/10.1080/00313020310001602576
Chooi Fun, Leong ; Raudhawati, Osman ; Cheong, Soon Keng ; Sivagengei, Kulaveerasingam ; Hussin, Noor Hamidah. / Epithelial membrane antigen (EMA) or MUC1 expression in monocytes and monoblasts. In: Pathology. 2003 ; Vol. 35, No. 5. pp. 422-427.
@article{51f8e31e51b44e08b207d3503ebcc5f8,
title = "Epithelial membrane antigen (EMA) or MUC1 expression in monocytes and monoblasts",
abstract = "Aims: Epithelial membrane antigen (EMA) or MUC1 belongs to a heterogeneous group of heavily glycosylated proteins and is expressed in most normal and epithelial neoplastic cells. EMA is also expressed in plasma cells, anaplastic large cell lymphoma (Ki-1 antigen), malignant histiocytosis and erythroleukaemia. In 1996, Cheong et al. (Hematology 1996; 1: 223) demonstrated the positive expression of EMA in monoblasts. Since there were very few useful markers for differentiating subtypes of acute myeloid leukaemia with a monocytic component from the those without, a study was conducted to evaluate the prevalence of EMA expression and its relationship with known markers for monocytic-macrophage lineage (CD11c, CD14 and intracellular CD68) in monocytes and monoblasts. Methods: EMA detection was performed by flow cytometry in monocytes and monoblasts. EMA expression was compared with other known markers of monocytic-macrophage lineage (CD11c, CD14 and intracellular CD68). Samples of purified monocytes were obtained from 20 healthy volunteers. Twenty-two cases of monocytic AML (M4 and M5) were studied and controls were selected from 20 cases of acute lymphoblastic leukaemia (ALL) and 18 cases of non-monocytic AML (MO, M1, M2, M3, and M7). Results: EMA was shown to be expressed strongly on the surface of all purified monocytes. EMA expression was observed on blast cells in 18/22 (81.8{\%}) cases of AML M4 and M5, but not in that of non-monocytic AML or ALL. In this study EMA monoclonal antibody has demonstrated a strong association (P < 0.001) with all the other known markers of monocytic-macrophage lineage in acute leukaemia subtypes. EMA had also shown 100{\%} specificity and 81.8{\%} sensitivity in the diagnosis of AML M4 and M5. Conclusions: The monoclonal antibody EMA (clone E29) is a useful marker in the classification of acute myeloid leukaemia and can be used as a supplementary analysis for the diagnosis of acute leukemia with monocytic involvement.",
keywords = "Acute myeloid leukaemia, Acute myeloid leukemia, EMA, Monoblasts, Monocytes",
author = "{Chooi Fun}, Leong and Osman Raudhawati and Cheong, {Soon Keng} and Kulaveerasingam Sivagengei and Hussin, {Noor Hamidah}",
year = "2003",
month = "10",
doi = "10.1080/00313020310001602576",
language = "English",
volume = "35",
pages = "422--427",
journal = "Pathology",
issn = "0031-3025",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Epithelial membrane antigen (EMA) or MUC1 expression in monocytes and monoblasts

AU - Chooi Fun, Leong

AU - Raudhawati, Osman

AU - Cheong, Soon Keng

AU - Sivagengei, Kulaveerasingam

AU - Hussin, Noor Hamidah

PY - 2003/10

Y1 - 2003/10

N2 - Aims: Epithelial membrane antigen (EMA) or MUC1 belongs to a heterogeneous group of heavily glycosylated proteins and is expressed in most normal and epithelial neoplastic cells. EMA is also expressed in plasma cells, anaplastic large cell lymphoma (Ki-1 antigen), malignant histiocytosis and erythroleukaemia. In 1996, Cheong et al. (Hematology 1996; 1: 223) demonstrated the positive expression of EMA in monoblasts. Since there were very few useful markers for differentiating subtypes of acute myeloid leukaemia with a monocytic component from the those without, a study was conducted to evaluate the prevalence of EMA expression and its relationship with known markers for monocytic-macrophage lineage (CD11c, CD14 and intracellular CD68) in monocytes and monoblasts. Methods: EMA detection was performed by flow cytometry in monocytes and monoblasts. EMA expression was compared with other known markers of monocytic-macrophage lineage (CD11c, CD14 and intracellular CD68). Samples of purified monocytes were obtained from 20 healthy volunteers. Twenty-two cases of monocytic AML (M4 and M5) were studied and controls were selected from 20 cases of acute lymphoblastic leukaemia (ALL) and 18 cases of non-monocytic AML (MO, M1, M2, M3, and M7). Results: EMA was shown to be expressed strongly on the surface of all purified monocytes. EMA expression was observed on blast cells in 18/22 (81.8%) cases of AML M4 and M5, but not in that of non-monocytic AML or ALL. In this study EMA monoclonal antibody has demonstrated a strong association (P < 0.001) with all the other known markers of monocytic-macrophage lineage in acute leukaemia subtypes. EMA had also shown 100% specificity and 81.8% sensitivity in the diagnosis of AML M4 and M5. Conclusions: The monoclonal antibody EMA (clone E29) is a useful marker in the classification of acute myeloid leukaemia and can be used as a supplementary analysis for the diagnosis of acute leukemia with monocytic involvement.

AB - Aims: Epithelial membrane antigen (EMA) or MUC1 belongs to a heterogeneous group of heavily glycosylated proteins and is expressed in most normal and epithelial neoplastic cells. EMA is also expressed in plasma cells, anaplastic large cell lymphoma (Ki-1 antigen), malignant histiocytosis and erythroleukaemia. In 1996, Cheong et al. (Hematology 1996; 1: 223) demonstrated the positive expression of EMA in monoblasts. Since there were very few useful markers for differentiating subtypes of acute myeloid leukaemia with a monocytic component from the those without, a study was conducted to evaluate the prevalence of EMA expression and its relationship with known markers for monocytic-macrophage lineage (CD11c, CD14 and intracellular CD68) in monocytes and monoblasts. Methods: EMA detection was performed by flow cytometry in monocytes and monoblasts. EMA expression was compared with other known markers of monocytic-macrophage lineage (CD11c, CD14 and intracellular CD68). Samples of purified monocytes were obtained from 20 healthy volunteers. Twenty-two cases of monocytic AML (M4 and M5) were studied and controls were selected from 20 cases of acute lymphoblastic leukaemia (ALL) and 18 cases of non-monocytic AML (MO, M1, M2, M3, and M7). Results: EMA was shown to be expressed strongly on the surface of all purified monocytes. EMA expression was observed on blast cells in 18/22 (81.8%) cases of AML M4 and M5, but not in that of non-monocytic AML or ALL. In this study EMA monoclonal antibody has demonstrated a strong association (P < 0.001) with all the other known markers of monocytic-macrophage lineage in acute leukaemia subtypes. EMA had also shown 100% specificity and 81.8% sensitivity in the diagnosis of AML M4 and M5. Conclusions: The monoclonal antibody EMA (clone E29) is a useful marker in the classification of acute myeloid leukaemia and can be used as a supplementary analysis for the diagnosis of acute leukemia with monocytic involvement.

KW - Acute myeloid leukaemia

KW - Acute myeloid leukemia

KW - EMA

KW - Monoblasts

KW - Monocytes

UR - http://www.scopus.com/inward/record.url?scp=0142209273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142209273&partnerID=8YFLogxK

U2 - 10.1080/00313020310001602576

DO - 10.1080/00313020310001602576

M3 - Article

C2 - 14555387

AN - SCOPUS:0142209273

VL - 35

SP - 422

EP - 427

JO - Pathology

JF - Pathology

SN - 0031-3025

IS - 5

ER -